RY 174.36 0.4783% SHOP 156.03 -2.1755% TD 76.42 0.2624% ENB 60.3 0.3495% BN 82.43 -0.4348% TRI 233.73 -0.1708% CNQ 43.48 0.023% CP 104.58 -0.994% CNR 147.02 -0.7091% BMO 139.94 0.5967% BNS 77.52 0.6361% CSU 4534.73 -0.2797% CM 90.65 -2.0318% MFC 44.29 0.5448% ATD 80.14 -0.5584% NGT 54.55 -0.6737% TRP 66.74 0.3006% SU 50.86 0.494% WCN 247.06 -0.6195% L 191.14 0.0366%

Thermo Fisher Scientific Inc

Healthcare US TMO

526.07USD
-1.11(0.21%)

Last update at 2024-12-27T21:10:00Z

Day Range

523.00528.28
LowHigh

52 Week Range

415.32608.22
LowHigh

Fundamentals

  • Previous Close 527.18
  • Market Cap204410.11M
  • Volume926731
  • P/E Ratio34.71
  • Dividend Yield0.26%
  • EBITDA10841.00M
  • Revenue TTM43421.00M
  • Revenue Per Share TTM112.05
  • Gross Profit TTM 18998.00M
  • Diluted EPS TTM15.24

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 7835.00M 8841.00M 7225.00M 4070.00M 3262.00M
Minority interest -10.00000M -3.00000M - - -
Net income 6950.00M 7725.00M 6375.00M 3696.00M 2938.00M
Selling general administrative 7127.00M 6842.00M 6930.00M 6144.00M 6057.00M
Selling and marketing expenses - - - - -
Gross profit 19500.00M 20234.00M 16505.00M 11827.00M 11364.00M
Reconciled depreciation 3381.00M 2592.00M 2325.00M 2277.00M 2267.00M
Ebit 8393.00M 10028.00M 7794.00M 4594.00M 3979.00M
Ebitda 12056.00M 12166.00M 10202.00M 6610.00M 6246.00M
Depreciation and amortization 3663.00M 2138.00M 2408.00M 2016.00M 2267.00M
Non operating income net other -4.00000M -655.00000M -16.00000M 152.00M -
Operating income 8393.00M 10028.00M 7794.00M 4594.00M 3783.00M
Other operating expenses 36408.00M 28986.00M 24325.00M 21361.00M 20525.00M
Interest expense 726.00M 536.00M 553.00M 676.00M 667.00M
Tax provision 703.00M 1109.00M 850.00M 374.00M 324.00M
Interest income 272.00M 43.00M 488.00M 224.00M 137.00M
Net interest income -454.00000M -493.00000M -488.00000M -452.00000M -530.00000M
Extraordinary items - - 0.00000M -8.00000M -117.00000M
Non recurring 114.00M 197.00M 99.00M -413.00000M 50.00M
Other items - - - - -
Income tax expense 703.00M 1109.00M 850.00M 374.00M 324.00M
Total revenue 44915.00M 39211.00M 32218.00M 25542.00M 24358.00M
Total operating expenses 10993.00M 10009.00M 8612.00M 7646.00M 7531.00M
Cost of revenue 25415.00M 18977.00M 15713.00M 13715.00M 12994.00M
Total other income expense net -558.00000M -1187.00000M -569.00000M -524.00000M -41.00000M
Discontinued operations - - - - -
Net income from continuing ops 6960.00M 7728.00M 6375.00M 3696.00M 2938.00M
Net income applicable to common shares 6950.00M 7725.00M 6375.00M 3696.00M 2938.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 97154.00M 95123.00M 69052.00M 58381.00M 56232.00M
Intangible assets 17478.00M 20146.00M 12685.00M 14014.00M 14978.00M
Earning assets - - - - -
Other current assets 1644.00M 1640.00M 1131.00M 1172.00M 922.00M
Total liab 53006.00M 54146.00M 34535.00M 28706.00M 28646.00M
Total stockholder equity 43978.00M 40793.00M 34507.00M 29675.00M 27586.00M
Deferred long term liab 2849.00M 3837.00M 1794.00M 2192.00M 2265.00M
Other current liab 5449.00M 5377.00M 4230.00M 2685.00M 4532.00M
Common stock 441.00M 439.00M 437.00M 434.00M 432.00M
Capital stock 441.00M 439.00M 437.00M 434.00M 432.00M
Retained earnings 41910.00M 35431.00M 28116.00M 22092.00M 18696.00M
Other liab 5689.00M 8138.00M 5134.00M 4849.00M 4651.00M
Good will 41196.00M 41924.00M 26041.00M 25714.00M 25347.00M
Other assets 2224.00M 3013.00M 1629.00M 1245.00M 1053.00M
Cash 8524.00M 4477.00M 10325.00M 2399.00M 2103.00M
Cash and equivalents 8524.00M 4477.00M 10325.00M 2399.00M 2103.00M
Total current liabilities 17010.00M 13436.00M 10304.00M 6197.00M 6147.00M
Current deferred revenue 2601.00M 2655.00M 1271.00M 916.00M 809.00M
Net debt 25964.00M 30393.00M 11410.00M 15353.00M 16887.00M
Short term debt 5579.00M 2537.00M 2628.00M 676.00M 1271.00M
Short long term debt 5579.00M 2537.00M 2628.00M 676.00M 1271.00M
Short long term debt total 34488.00M 34870.00M 21735.00M 17752.00M 18990.00M
Other stockholder equity 1627.00M 4923.00M 5954.00M 7149.00M 8458.00M
Property plant equipment 9280.00M 8333.00M 5912.00M 4749.00M 4165.00M
Total current assets 25229.00M 20113.00M 21957.00M 11893.00M 10625.00M
Long term investments - - - 67.00M 64.00M
Net tangible assets -14544.00000M -21182.00000M -4219.00000M -10053.00000M -12739.00000M
Short term investments 2.00M - 28.00M 37.00M 31.00M
Net receivables 9427.00M 8945.00M 6472.00M 4952.00M 4595.00M
Long term debt 28909.00M 32333.00M 19107.00M 17076.00M 17719.00M
Inventory 5634.00M 5051.00M 4029.00M 3370.00M 3005.00M
Accounts payable 3381.00M 2867.00M 2175.00M 1920.00M 1615.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 54.00M 62.00M - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3099.00000M -2329.00000M -2807.00000M -2679.00000M -2498.00000M
Additional paid in capital - - - - -
Common stock total equity 441.00M 439.00M 437.00M 434.00M 432.00M
Preferred stock total equity - - - - -
Retained earnings total equity 41910.00M 35431.00M 28116.00M 22092.00M 18696.00M
Treasury stock - -8922.00000M -6818.00000M -5236.00000M -3665.00000M
Accumulated amortization - - - - -
Non currrent assets other -2849.00000M 4352.00M 2457.00M 1850.00M 1051.00M
Deferred long term asset charges - - - - -
Non current assets total 69701.00M 71997.00M 45466.00M 45243.00M 44554.00M
Capital lease obligations - - - - -
Long term debt total 28909.00M 32333.00M 19107.00M 17076.00M 17719.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2159.00000M -21932.00000M -1510.00000M -1487.00000M -1253.00000M
Change to liabilities 648.00M 479.00M 59.00M 476.00M 159.00M
Total cashflows from investing activities -2159.00000M -21932.00000M -1510.00000M -1487.00000M -1253.00000M
Net borrowings 654.00M 8911.00M 2747.00M -1405.00000M -1556.00000M
Total cash from financing activities -2810.00000M 6581.00M 959.00M -3118.00000M -2237.00000M
Change to operating activities -442.00000M -1558.00000M -395.00000M -248.00000M -81.00000M
Net income 6960.00M 7728.00M 6375.00M 3696.00M 2938.00M
Change in cash 4046.00M -5845.00000M 7914.00M 305.00M 756.00M
Begin period cash flow 4491.00M 10336.00M 2422.00M 2117.00M 1361.00M
End period cash flow 8537.00M 4491.00M 10336.00M 2422.00M 2117.00M
Total cash from operating activities 9154.00M 9543.00M 8289.00M 4973.00M 4543.00M
Issuance of capital stock - - - 153.00M 0.00000M
Depreciation 3381.00M 2592.00M 2325.00M 2277.00M 2267.00M
Other cashflows from investing activities 84.00M -34.00000M -36.00000M -561.00000M -495.00000M
Dividends paid -455.00000M -395.00000M -337.00000M -297.00000M 266.00M
Change to inventory -825.00000M -1065.00000M -508.00000M -458.00000M -324.00000M
Change to account receivables -430.00000M -204.00000M -1302.00000M -225.00000M -366.00000M
Sale purchase of stock -3000.00000M -2000.00000M -1500.00000M -1500.00000M -500.00000M
Other cashflows from financing activities 4710.00M -91.00000M -147.00000M 8350.00M 5699.00M
Change to netincome -179.00000M 781.00M -112.00000M -385.00000M -185.00000M
Capital expenditures 2243.00M 2523.00M 1474.00M 926.00M 758.00M
Change receivables -430.00000M -204.00000M -1302.00000M -225.00000M -366.00000M
Cash flows other operating -401.00000M -724.00000M 7827.00M 3288.00M 2992.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes 4185.00M -6039.00000M 7738.00M 368.00M 1053.00M
Change in working capital -1049.00000M -1558.00000M -395.00000M -619.00000M -530.00000M
Stock based compensation 307.00M 230.00M 196.00M 181.00M 181.00M
Other non cash items 550.00M 957.00M 340.00M -214.00000M 106.00M
Free cash flow 6911.00M 7020.00M 6815.00M 4047.00M 3785.00M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TMO
Thermo Fisher Scientific Inc
-1.11 0.21% 526.07 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
0.09 0.04% 231.10 29.09 28.01 5.67 3.20 6.00 19.09
IDXX
IDEXX Laboratories Inc
-2.18 0.52% 414.93 49.99 45.66 11.29 27.85 11.46 34.46
IQV
IQVIA Holdings Inc
-0.86 0.43% 199.39 37.82 19.68 2.76 7.20 3.61 17.03
A
Agilent Technologies Inc
-0.29 0.21% 135.54 31.97 25.84 6.23 6.96 6.62 23.01

Reports Covered

Stock Research & News

Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc

168 Third Avenue, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Marc N. Casper Chairman, Pres & CEO 1968
Mr. Stephen Williamson Sr. VP & CFO 1967
Mr. Michel Lagarde Exec. VP & COO 1975
Mr. Gianluca Pettiti Exec. VP 1979
Mr. Joseph R. Holmes VP & Chief Accounting Officer 1980
Mr. Ryan J. Snyder Sr. VP & Chief Information Officer NA
Dr. Karen E. Nelson Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. Rafael Tejada VP of Investor Relations NA
Mr. Michael A. Boxer Esq. Sr. VP, Gen. Counsel & Sec. 1962
Ms. Sandy B. Pound VP & Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.